A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.

PubWeight™: 2.32‹?› | Rank: Top 2%

🔗 View Article (PMID 17087938)

Published in Gastroenterology on September 19, 2006


Josep M Llovet1, Yingbei Chen, Elisa Wurmbach, Sasan Roayaie, M Isabel Fiel, Myron Schwartz, Swan N Thung, Gregory Khitrov, Weijia Zhang, Augusto Villanueva, Carlo Battiston, Vincenzo Mazzaferro, Jordi Bruix, Samuel Waxman, Scott L Friedman

Author Affiliations

1: Mount Sinai Liver Cancer Program, Department of Medicine, Mount Sinai School of Medicine, New York 10029, USA. Josep.Llovet@mssm.edu

Articles citing this

Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest (2007) 6.56

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35

Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03

Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39

LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res (2013) 1.91

Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med (2010) 1.86

Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol (2009) 1.81

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77

Viral hepatocarcinogenesis. Oncogene (2010) 1.73

Experimental models of hepatocellular carcinoma. J Hepatol (2008) 1.61

Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci U S A (2013) 1.51

UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma. Cancer Cell (2014) 1.50

Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res (2012) 1.44

Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol (2010) 1.40

Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 1.33

High-throughput assessment of CpG site methylation for distinguishing between HCV-cirrhosis and HCV-associated hepatocellular carcinoma. Mol Genet Genomics (2010) 1.27

Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol (2008) 1.26

Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol (2012) 1.26

Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology (2008) 1.21

Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent) (2008) 1.20

Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clin Cancer Res (2010) 1.17

Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des (2013) 1.16

Molecular pathology of hepatic neoplasms: classification and clinical significance. Patholog Res Int (2011) 1.14

Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics (2012) 1.10

A feedback inhibition between miRNA-127 and TGFβ/c-Jun cascade in HCC cell migration via MMP13. PLoS One (2013) 1.10

Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol (2010) 1.10

Telomerase activated thymidine analogue pro-drug is a new molecule targeting hepatocellular carcinoma. J Hepatol (2014) 1.09

Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology (2011) 1.07

JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma. Mol Cancer (2009) 1.07

Enhancement patterns and signal-intensity characteristics of small hepatocellular carcinoma in cirrhosis: pathologic basis and diagnostic challenges. Eur Radiol (2007) 1.03

Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness. Mol Med (2009) 0.97

Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol (2014) 0.97

Hepatitis C virus and hepatocarcinogenesis. Clin Mol Hepatol (2012) 0.96

An overview of biomarkers for the diagnosis of hepatocellular carcinoma. Hepat Mon (2012) 0.96

Genome-wide transcriptional reorganization associated with senescence-to-immortality switch during human hepatocellular carcinogenesis. PLoS One (2013) 0.95

Autophagy inhibits oxidative stress and tumor suppressors to exert its dual effect on hepatocarcinogenesis. Cell Death Differ (2014) 0.95

Cortactin is a sensitive biomarker relative to the poor prognosis of human hepatocellular carcinoma. World J Surg Oncol (2013) 0.95

Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett (2013) 0.95

Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma. Free Radic Biol Med (2014) 0.94

Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. Hepatology (2014) 0.92

Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma. PLoS One (2013) 0.91

Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. Liver Transpl (2011) 0.90

Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol (2015) 0.90

Paracrine activation of hepatic stellate cells in platelet-derived growth factor C transgenic mice: evidence for stromal induction of hepatocellular carcinoma. Int J Cancer (2013) 0.90

Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma. Anticancer Agents Med Chem (2011) 0.89

The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol (2013) 0.89

Telomeres, NAFLD and Chronic Liver Disease. Int J Mol Sci (2016) 0.89

Novel serum markers of fibrosis progression for the follow-up of hepatitis C virus-infected patients. Am J Pathol (2009) 0.88

Molecular mechanisms underlying hepatocellular carcinoma. Viruses (2009) 0.87

Systemic therapy of hepatocellular carcinoma: current status and future perspectives. World J Gastroenterol (2014) 0.86

Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol (2015) 0.85

Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma. Mol Cancer (2012) 0.85

Potential targets for molecular imaging of apoptosis resistance in hepatocellular carcinoma. Biomed Imaging Interv J (2011) 0.84

Cell-block procedure in endoscopic ultrasound-guided-fine-needle-aspiration of gastrointestinal solid neoplastic lesions. World J Gastrointest Endosc (2015) 0.84

Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles. Mol Imaging (2011) 0.84

Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol (2015) 0.84

Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol (2012) 0.83

Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int (2015) 0.83

Involvement of insulin-like growth factor-binding protein-3 in the effects of histone deacetylase inhibitor MS-275 in hepatoma cells. J Biol Chem (2011) 0.82

Identification of SLAMF3 (CD229) as an inhibitor of hepatocellular carcinoma cell proliferation and tumour progression. PLoS One (2013) 0.82

Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy. J Gastroenterol (2013) 0.82

Dysplastic nodules with glypican-3 positive immunostaining: a risk for early hepatocellular carcinoma. PLoS One (2014) 0.82

Overexpression of platelet-derived growth factor receptor alpha promotes tumor progression and indicates poor prognosis in hepatocellular carcinoma. Oncotarget (2014) 0.82

Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, and Prevention. J Clin Transl Hepatol (2013) 0.81

Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report. World J Gastroenterol (2010) 0.81

Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis. World J Hepatol (2009) 0.81

Generation of functional CD8+ T cells by human dendritic cells expressing glypican-3 epitopes. J Exp Clin Cancer Res (2010) 0.81

Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis. BMC Cancer (2014) 0.81

Molecular events in hepatic preneoplasia: a review. Exp Mol Pathol (2010) 0.80

Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence. World J Gastroenterol (2009) 0.80

Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci (2013) 0.79

Positive immunostaining of Sal-like protein 4 is associated with poor patient survival outcome in the large and undifferentiated Korean hepatocellular carcinoma. Ann Surg Treat Res (2016) 0.78

A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma. Funct Integr Genomics (2011) 0.78

An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis. Cell Oncol (Dordr) (2012) 0.78

The expression of embryonic liver development genes in hepatitis C induced cirrhosis and hepatocellular carcinoma. Cancers (Basel) (2012) 0.77

GPC-3 in hepatocellular carcinoma: current perspectives. J Hepatocell Carcinoma (2016) 0.77

Lymphatic vessel endothelial hyaluronan receptor-1 is a novel prognostic indicator for human hepatocellular carcinoma. Mol Clin Oncol (2013) 0.77

High TSC22D3 and low GBP1 expression in the liver is a risk factor for early recurrence of hepatocellular carcinoma. Exp Ther Med (2011) 0.77

Qualitative analysis of small (≤2 cm) regenerative nodules, dysplastic nodules and well-differentiated HCCs with gadoxetic acid MRI. BMC Med Imaging (2016) 0.75

Discrimination of cirrhotic nodules, dysplastic lesions and hepatocellular carcinoma by their vibrational signature. J Transl Med (2016) 0.75

Molecular Profiling and Research of Therapeutic Targets. Dig Dis (2015) 0.75

Characterization of a new monoclonal anti-glypican-3 antibody specific to the hepatocellular carcinoma cell line, HepG2. World J Hepatol (2017) 0.75

Seminal vesicle metastasis after partial hepatectomy for hepatocellular carcinoma. BMC Cancer (2011) 0.75

A pre-neoplastic epigenetic field defect in HCV-infected liver at transcription factor binding sites and polycomb targets. Oncogene (2016) 0.75

Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol (2016) 0.75

Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma. J Hepatocell Carcinoma (2014) 0.75

The growth pattern of transplanted normal and nodular hepatocytes. Histochem Cell Biol (2011) 0.75

Hepatitis C virus NS4B protein induces epithelial-mesenchymal transition by upregulation of Snail. Virol J (2017) 0.75

How to Differentiate Borderline Hepatic Nodules in Hepatocarcinogenesis: Emphasis on Imaging Diagnosis. Liver Cancer (2017) 0.75

SLC2A2 (GLUT2) as a novel prognostic factor for hepatocellular carcinoma. Oncotarget (2017) 0.75

Articles by these authors

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Hepatocellular carcinoma. Lancet (2003) 22.54

Hepatocellular carcinoma. Lancet (2012) 18.09

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20

Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75

Accuracy and calibration of commercial oligonucleotide and custom cDNA microarrays. Nucleic Acids Res (2002) 6.70

Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93

Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis (2010) 5.85

Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78

The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33

Pathogenesis of liver fibrosis. Annu Rev Pathol (2011) 5.27

Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol (2008) 5.24

Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol (2006) 5.17

Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05

Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35

Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol (2013) 4.28

miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15

Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03

Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77

Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol (2013) 3.71

Mechanisms of action of arsenic trioxide. Cancer Res (2002) 3.68

Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology (2015) 3.63

Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int (2012) 3.46

A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res (2012) 3.39

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood (2009) 3.35

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04

Management of HCC. J Hepatol (2012) 3.03

Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00

Robust cellular reprogramming occurs spontaneously during liver regeneration. Genes Dev (2013) 2.96

HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. J Clin Invest (2003) 2.89

Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol (2011) 2.82

Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79

New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology (2013) 2.76

Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J Am Soc Nephrol (2008) 2.74

Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Gut (2012) 2.70

Three-year efficacy and acceptability of the GyneFix 200 intrauterine system. Contraception (2004) 2.69

All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A (2004) 2.67

Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66

The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl (2004) 2.65

Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology (2010) 2.61

Differential gene expression following early renal ischemia/reperfusion. Kidney Int (2003) 2.60

The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood (2007) 2.58

Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology (2004) 2.54

Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology (2004) 2.54

Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol (2012) 2.53

Activation of hepatic stellate cells--a key issue in liver fibrosis. Front Biosci (2002) 2.49

Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42